Precision medicine: the rifle vs. shotgun approach to cancer treatment
Why does one person respond favorably to lung cancer treatment while another does not? The answer lies in their DNA. Just 20 years ago, lung cancer was broadly categorized into two groups:  non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Relatively recently, the treatment of NSCLC shifted from chemotherapy as a single treatment optionRead more …Precision medicine: the rifle vs. shotgun approach to cancer treatment originally appeared inKevinMD.com. (Source: Kevin, M.D. - Medical Weblog)
Source: Kevin, M.D. - Medical Weblog - June 20, 2022 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/post-author/hirva-mamdani" rel="tag" data-wpel-link="internal" > Hirva Mamdani, MD < /a > < /span > Tags: Conditions Oncology/Hematology Source Type: blogs

Last Month in Oncology with Dr. Bishal Gyawali
By BISHAL GYAWALI MD  Long list of news in lung cancer September was an important month in oncology—especially for lung cancer. The World Conference in Lung Cancer (WCLC) 2018 gave us some important practice-changing results, also leading to four NEJM publications. The trial with most public health impact is unfortunately not published yet. It’s the NELSON trial that randomised more than 15000 asymptomatic people at high risk of lung cancer to either CT-based screening for lung cancer or to no screening and found a significant reduction in lung cancer mortality rates among the screened cohort compared with the contr...
Source: The Health Care Blog - January 4, 2019 Category: Consumer Health News Authors: matthew holt Tags: Research Bishal Gyawali Breast cancer Cancer drugs Clinical Trials health spending immunotherapy Lung cancer Oncology pembrolizumab Source Type: blogs